Dupilumab Improves Asthma Control, and Allergic Rhinitis-Related Health-Related Quality of Life in Children With Uncontrolled Persistent Asthma With Comorbid Allergic Rhinitis

Abstract

Children with asthma frequently have comorbid allergic rhinitis (AR). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4/13, key and central drivers of type 2 (T2) inflammation in multiple diseases. VOYAGE, a 52-week, randomized, double-blind, placebo-controlled, phase 3 study (NCT02948959), evaluated dupilumab efficacy and safety in children aged 6–11 years with uncontrolled persistent asthma. We assessed the impact of dupilumab on asthma control (interviewer-administered 7-Item Asthma Control Questionnaire [ACQ-7-IA]) and AR-related health-related quality of life (HRQoL) (interviewer-administered Pediatric Rhinoconjunctivitis Quality of Life Questionnaire [PRQLQ-IA]) in children with a T2 inflammatory asthma phenotype (baseline blood eosinophils ≥150 cells/μL or FeNO ≥20 ppb), and co-existing AR.